DBVT earnings analysis
What we found in DBVT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
DBV Technologies reported Q2 2026 results with zero revenue, consistent with prior expectations, while net loss increased to $50.4 million from $41.9 million year-over-year. The operating expenses rose primarily due to escalated sales and marketing expenses ahead of expected BLA submissions with greater operational capacity requirements.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Total Revenue at $0
- The company did not generate any revenue from operating activities for Q2 2026, consistent with Q2 2025.
- Net Loss Increases
- Net loss escalated to $50.4 million in Q2 2026, a 20% increase from $41.9 million in Q2 2025.
- Research and Development Expenses Down
- R&D expenses decreased to $31.2 million in Q2 2026 from $33.7 million in Q2 2025, a 7% reduction.
- Sales & Marketing Expenses Surge
- Sales and marketing expenses soared to $5.5 million, up 1225% from $0.4 million in Q2 2025, reflecting increased commercialization readiness efforts.
- General & Administrative Costs Rise
- G&A expenses rose to $14.6 million, a 72% increase from $8.5 million in Q2 2025, driven by expansion of corporate infrastructure.
- Cash Balance Declines
- The cash balance as of June 30, 2026, was $174.9 million, down from $194.2 million at the end of 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Net Losses
- Net losses rose to $50.4 million this quarter, indicating higher costs without revenue.
- Reliance on Third-Party Manufacturers
- Dependence on Sanofi and FAREVA for manufacturing exposes the company to risks related to capacity and compliance issues.
- Foreign Currency Fluctuations
- Risks from fluctuations between the Euro and U.S. dollar resulted in a significant foreign currency translation adjustment of $(5.3) million.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.12
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
What came before.
- 10-Q · April 30, 2026
- DBV Technologies' latest 10-Q report reveals continued operational challenges, with operating expenses surging 78% year-over-year alongside rising net losses. Despite these headwinds, the company maintains a robust cash…
- 10-K · April 30, 2026
- DBV Technologies reported a challenging year with revenue declines and substantial operating losses. Despite maintaining cash reserves for ongoing operations, the company is facing scrutiny over its financial…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DBVT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever